A Clinical Study Evaluating Inhaled Aviptadil on COVID-19

Launched by CENTURION PHARMA · Apr 13, 2021

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1.18 years and older women or men, under 70 years old
• • 2.Patients with positive SARS-CoV-2 real time PCR result and an appearance in line with COVID-19 pneumonia on thorax CT
• • 3. Need for oxygen support or SpO2 \<94 in room air
• • 4. Patients who can use a nebulizer (with assistance when necessary)
• • 5.Patients who are willing and capable (mentally and physically) who can sign a written informed consent form, to participate in all aspects of the study, to participate in the planned visits and to comply with the terms of the protocol.
• Exclusion Criteria:
• • 1. Intensive care admission
• • 2. The need for mechanical ventilation
• • 3. Patients with previously known organ (kidney, heart and liver) failure
• • \* To be determined as previously known heart failure (EF \<30), previously known liver failure (Child-Pugh C) and previously known renal failure (Cr.clerance \<30).
• • 4. COVID-19 disease with no indication for hospitalization
• • 5. Participants in another clinical trial
• • 6. Pregnancy or lactation
• • 7. Solid organ or stem cell transplantation story
• • 8. Patients with collagen tissue disease
• • 9. Use of immunosuppressive therapy
• • 10. Procalcitonin ≥2 (baseline visit)
• • 11. Under 18 years old
• • 12. Those who had myocardial infarction in the last 3 months
• • 13. Those who do not have the capacity to understand the possible results, scope and nature of the study due to legal insufficiency and / or other reasons.
• • 14. Those who, in the opinion of the investigator, cannot continue the treatment protocol regularly or cannot cooperate
• • 15. Presence of malignancy
• • 16. Patients with neurological diseases